5.21 USD
▲+0.49+10.38%
盘后 5.32 +2.11%
2026-11-19
市值
$1.15B
市盈率
—
EPS
-0.61
股息率
—
52 周区间
4.13 – 7.01
成交量
12.30M
Beta
0.30
目标价
10.83
52W 低 4.1352W 高 7.01
价格走势
公司简介
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company’s lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. Savara Inc. was founded in 2007 and is headquartered in Yardley, Pennsylvania.